<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Mutational Process-Driven Subclonal Evolution Theory - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-3</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-3</p>
                <p><strong>Name:</strong> Mutational Process-Driven Subclonal Evolution Theory</p>
                <p><strong>Type:</strong> specific</p>
                <p><strong>Theory Query:</strong> Build a theory of what drives lung adenocarcinomas that lack known driver alterations in the RTK/RAS/RAF pathway, based on the following results.</p>
                <p><strong>Description:</strong> In lung adenocarcinomas lacking dominant truncal drivers, tumor evolution is driven by ongoing mutagenic processes—particularly APOBEC cytidine deaminase activity enriched in late/subclonal mutations—that generate subclonal driver mutations in genes like EP300, TGFBR1, and AKAP9, creating spatial and temporal heterogeneity and enabling evolutionary escape from selective pressures including therapy, thus requiring therapeutic strategies targeting truncal alterations or common dependencies rather than subclonal drivers.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> claude-sonnet-4-5-20250929</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: APOBEC-Driven Subclonal Driver Generation Principle</h3>
            <p><strong>Statement:</strong> In lung adenocarcinomas, an APOBEC cytidine deaminase mutational signature (C>T and C>G mutations at TpC motifs) is enriched in late/subclonal mutations compared to truncal mutations, generates subclonal driver mutations in chromatin modifiers (EP300), signaling regulators (TGFBR1, AKAP9), and other genes in an ongoing process throughout tumor evolution, shows spatial heterogeneity across tumor regions, correlates with APOBEC3B mRNA expression in affected regions, and is associated with worse survival in early lung adenocarcinoma compared to other mutational signatures.</p>
            <p><strong>Domain/Scope:</strong> Applies to lung adenocarcinomas analyzed by multiregion whole-exome or whole-genome sequencing with mutational signature analysis; APOBEC signature identified by trinucleotide context analysis; more pronounced in lung adenocarcinoma than squamous cell carcinoma in analyzed cohorts; enrichment in branch/subclonal mutations compared to trunk requires temporal/spatial sampling; associated with disease progression in early-stage tumors.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>APOBEC signature can also be present in truncal mutations but shows enrichment in branches</li>
                <li>APOBEC3B expression varies across tumor regions creating spatial heterogeneity in mutational activity</li>
                <li>Not all tumors show APOBEC signature; alternative signatures include smoking-associated and mismatch repair signatures</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>APOBEC-associated mutational process (C>T and C>G at TpC) enriched in late/subclonal mutations and implicated in generating subclonal driver mutations (EP300, TGFBR1, AKAP9) in LUAD regions with regional APOBEC3B mRNA expression correlation; enrichment increased over time (late mutations) with spatial heterogeneity <a href="../results/extraction-result-95.html#e95.19" class="evidence-link">[e95.19]</a> </li>
    <li>EP300 branch mutations in APOBEC context identified as potential subclonal driver events in multiregion WES/WGS cohort <a href="../results/extraction-result-95.html#e95.8" class="evidence-link">[e95.8]</a> </li>
    <li>TGFBR1 branch mutation in APOBEC context found in LUAD region of L002 as subclonal driver within APOBEC-enriched subclone <a href="../results/extraction-result-95.html#e95.5" class="evidence-link">[e95.5]</a> </li>
    <li>AKAP9 APOBEC-context branch mutation reported among subclonal driver events in study tumors <a href="../results/extraction-result-95.html#e95.7" class="evidence-link">[e95.7]</a> </li>
    <li>APOBEC mutational signature associated with worse survival compared to mismatch repair signature in early lung adenocarcinoma (102 early lesions); associated with increased subclonal mutation burden <a href="../results/extraction-result-24.html#e24.25" class="evidence-link">[e24.25]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> APOBEC signatures are established, but their specific temporal and spatial dynamics in lung adenocarcinoma evolution and generation of subclonal drivers represents an incremental mechanistic advance.</p>            <p><strong>What Already Exists:</strong> APOBEC mutational signatures in cancer were described in pan-cancer analyses; APOBEC's role in generating mutations in multiple cancer types is established; subclonal heterogeneity in lung cancer is well-documented.</p>            <p><strong>What is Novel:</strong> The specific enrichment of APOBEC signature in subclonal versus truncal mutations in lung adenocarcinoma, the identification of specific subclonal APOBEC-context driver mutations (EP300, TGFBR1, AKAP9), spatial heterogeneity correlation with APOBEC3B expression, and prognostic associations in early disease represent refined mechanistic understanding.</p>
        <p><strong>References:</strong> <ul>
    <li>Alexandrov et al. (2013) Signatures of mutational processes in human cancer [APOBEC signature identification]</li>
    <li>Roberts et al. (2013) An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers [APOBEC in cancer]</li>
    <li>de Bruin et al. (2014) Spatial and temporal diversity in genomic instability processes defines lung cancer evolution [Subclonal APOBEC enrichment]</li>
    <li>Qian et al. (2020) Genomic underpinnings of tumor behavior in early lung adenocarcinoma [Prognostic associations]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Intratumor Heterogeneity and Therapeutic Implication Principle</h3>
            <p><strong>Statement:</strong> Multiregion sequencing of lung adenocarcinomas reveals that the majority of somatic mutations are subclonal (region-specific) rather than truncal (present in all regions), with key driver genes showing region-specific alterations (PIK3CA E542K in single region, regional EGFR L858R, regional structural variants), indicating that therapies targeting subclonal drivers will face limited efficacy due to untargeted tumor cell populations, while therapies targeting truncal alterations (TP53, STK11, EGFR amplification) or common dependencies have greater potential for durable response.</p>
            <p><strong>Domain/Scope:</strong> Applies to lung adenocarcinomas analyzed by multiregion sequencing (at least 3-4 regions per tumor); spatial heterogeneity patterns may vary by tumor size, stage, and prior treatment; proportion of truncal versus subclonal mutations varies by tumor but subclonal generally predominates in advanced disease; validated in cohort of 7 tumors with 25 regions total.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Small tumors or early-stage tumors may show less heterogeneity than advanced tumors</li>
                <li>Metastases may be clonally derived from subclones not fully represented in primary tumor sampling</li>
                <li>Copy number alterations can affect clonality estimates of point mutations through LOH</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>PIK3CA E542K mutation detected only in region R3 of tumor L008 (regional/heterogeneous event); authors note presence could suggest PI3K/mTOR pathway targeted therapy and could confer resistance to single-agent BRAF inhibition in that region only <a href="../results/extraction-result-95.html#e95.3" class="evidence-link">[e95.3]</a> </li>
    <li>EGFR L858R observed in two anatomically separate tumors from patient L003 inferred as independent clonal origins with parallel evolution of recurrent event rather than shared truncal event <a href="../results/extraction-result-95.html#e95.0" class="evidence-link">[e95.0]</a> </li>
    <li>PAX7 mutation became regionally heterogeneous due to copy-number loss in lymph node of L001, creating spatial variability in mutation status <a href="../results/extraction-result-95.html#e95.14" class="evidence-link">[e95.14]</a> </li>
    <li>ZFHX4 and ARHGAP35 branch mutations identified in LUAD region of L002 as region-specific driver candidates <a href="../results/extraction-result-95.html#e95.16" class="evidence-link">[e95.16]</a> </li>
    <li>NF1 disrupted by clustered translocations (structural variants) in tumor L008, representing region-specific structural alteration <a href="../results/extraction-result-95.html#e95.10" class="evidence-link">[e95.10]</a> </li>
    <li>Truncal events include TP53 mutations, STK11 mutations, EGFR amplification (ubiquitous in L001), and CDKN2A deletion observed as early events; authors discuss that genome doubling and chromosomal instability may complicate targeting truncal drivers <a href="../results/extraction-result-95.html#e95.4" class="evidence-link">[e95.4]</a> <a href="../results/extraction-result-95.html#e95.1" class="evidence-link">[e95.1]</a> <a href="../results/extraction-result-95.html#e95.12" class="evidence-link">[e95.12]</a> <a href="../results/extraction-result-95.html#e95.17" class="evidence-link">[e95.17]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> Intratumor heterogeneity and its therapeutic implications are established concepts; the specific characterization in lung adenocarcinoma represents incremental application rather than fundamentally new biology.</p>            <p><strong>What Already Exists:</strong> Intratumor heterogeneity in cancer is well-established from multiregion sequencing studies across cancer types; the concept of truncal versus branch mutations and implications for targeted therapy are recognized principles.</p>            <p><strong>What is Novel:</strong> The specific quantification and examples of subclonal driver heterogeneity in lung adenocarcinoma (PIK3CA, EGFR, structural variants), integration with mutational process dynamics (APOBEC), and explicit therapeutic strategy implications represent refined application to LUAD.</p>
        <p><strong>References:</strong> <ul>
    <li>Gerlinger et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing [Landmark heterogeneity study in RCC]</li>
    <li>de Bruin et al. (2014) Spatial and temporal diversity in genomic instability processes defines lung cancer evolution [Lung cancer heterogeneity]</li>
    <li>Jamal-Hanjani et al. (2017) Tracking the evolution of non-small-cell lung cancer [TRACERx study]</li>
    <li>McGranahan & Swanton (2017) Clonal heterogeneity and tumor evolution [Review of implications]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Lung adenocarcinomas with high APOBEC signature burden will show increased subclonal mutation rates over time compared to tumors with low APOBEC signature</li>
                <li>Tumors with elevated APOBEC3B expression will show ongoing generation of new subclonal mutations during therapy, contributing to adaptive resistance</li>
                <li>Multiregion sequencing of driver-negative tumors will reveal higher proportions of subclonal drivers compared to tumors with strong truncal oncogene drivers</li>
                <li>Single-biopsy genomic profiling will miss clinically relevant subclonal alterations present in unsampled tumor regions in >50% of cases</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Whether inhibition of APOBEC3B activity (if achievable pharmacologically) would slow tumor evolution and delay therapeutic resistance</li>
                <li>Whether therapies targeting truncal alterations in heterogeneous tumors will show superior durability compared to therapies targeting subclonal drivers even when the subclonal driver is detected in the biopsied region</li>
                <li>Whether liquid biopsy capturing circulating tumor DNA from multiple subclones will better represent tumor heterogeneity than single-site tissue biopsy</li>
                <li>Whether specific combinations of mutational signatures predict patterns of therapeutic resistance</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>Finding that APOBEC signature mutations are equally distributed between truncal and branch events would challenge the temporal enrichment model</li>
                <li>Demonstrating that subclonal driver mutations do not contribute to drug resistance or tumor evolution would contradict the heterogeneity implications</li>
                <li>Showing that APOBEC3B expression does not correlate with APOBEC signature in tumor regions would challenge the mechanistic link</li>
                <li>Finding that therapies targeting subclonal drivers are as effective as therapies targeting truncal drivers would challenge the therapeutic strategy implications</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>The relative contribution of APOBEC versus other mutational processes (smoking, mismatch repair deficiency) in different patient populations </li>
    <li>Whether APOBEC activity is continuous throughout tumor evolution or occurs in bursts ('kataegis') </li>
    <li>The drivers of APOBEC3B expression variation across tumor regions <a href="../results/extraction-result-95.html#e95.19" class="evidence-link">[e95.19]</a> </li>
    <li>Whether intratumor heterogeneity patterns differ between primary tumors and metastases </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>